Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review

In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks. Respiratory Syncytial Virus (RSV) hospitalisations and prevalence of palivizumab use in infants aged <6 months during...

Descripción completa

Detalles Bibliográficos
Autores principales: Belleudi, Valeria, Marchetti, Federico, Finocchietti, Marco, Davoli, Marina, Addis, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925248/
https://www.ncbi.nlm.nih.gov/pubmed/33748434
http://dx.doi.org/10.1136/bmjpo-2020-000985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925248/
https://www.ncbi.nlm.nih.gov/pubmed/33748434
http://dx.doi.org/10.1136/bmjpo-2020-000985

Ejemplares similares